Literature DB >> 12631135

Apolipoprotein E in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.

Maurizio Bruschi1, Paolo Catarsi, Giovanni Candiano, Maria Pia Rastaldi, Luca Musante, Francesco Scolari, Mary Artero, Michele Carraro, Alba Carrea, Gianluca Caridi, Cristina Zennaro, Simone Sanna-Cherchi, Fabio Battista Viola, Franco Ferrario, Francesco Perfumo, Gian Marco Ghiggeri.   

Abstract

BACKGROUND: Hyperlipemia characterizes nephrotic syndrome (NS) and contributes to the progression of the underlying nephropathy. The data in the literature support an implication of apolipoprotein E (apoE) in both hyperlipemia and focal segmental glomerulosclerosis (FSGS), a malignant condition associated with NS.
METHODS: The apoE genotype was determined in 209 nephrotic patients, who were classified according to age and their response to steroids as resistant children (N = 96) and adults (43), and steroid dependent (33) and steroid responder (37) children. A total of 123 presented the histological features of FSGS. In a subgroup of 28 patients, serum and urinary levels of apoE and renal deposits were evaluated by immunofluorescence.
RESULTS: The allelic frequencies of the three major haplotypes epsilon2, epsilon3, and epsilon4 were the same in nephrotic patients versus controls, and homozygosity for epsilon3epsilon3 was comparably the most frequent genotype (70 vs. 71%) followed by epsilon3epsilon4, epsilon2epsilon3, epsilon2epsilon4, epsilon4epsilon4. Serum levels of apoE were fivefold higher in NS and in FSGS patients than in controls, with a direct correlation with hypercholesterolemia and proteinuria. ApoE genotypes did not influence serum levels. Urinary levels were 1/10,000 of serum with an increment in nephrotic urines. Finally, immunofluorescence demonstrated the absence of apoE in sclerotic glomeruli, while comparably nephrotic patients with membranous nephropathy had an increased glomerular expression of apoE.
CONCLUSIONS: ApoE is dysregulated in NS with a marked increment in serum, which is a part of the complex lipid metabolism. Down-regulation of glomerular apoE instead is a peculiarity of FSGS and may contribute to the pathogenesis of the disease. The normal distribution of apoE genotypes in nephrotic patients with FSGS excludes a pathogenetic role of genetic variants.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631135     DOI: 10.1046/j.1523-1755.2003.00777.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

Review 1.  Systemic and renal lipids in kidney disease development and progression.

Authors:  Patricia Wahl; Gloria Michelle Ducasa; Alessia Fornoni
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-23

2.  Association of apoE gene expression and its gene polymorphism with nephrotic syndrome susceptibility: a meta-analysis of experimental and human studies.

Authors:  Tian-Biao Zhou; Yuan-Han Qin; Hui-Ling Xu
Journal:  Mol Biol Rep       Date:  2012-07-04       Impact factor: 2.316

3.  Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka and Homozygous Apolipoprotein E2/2 without Dyslipidemia, with Characteristic Electron-Dense Deposits.

Authors:  Akihiko Koshino; Chikako Takaeda; Takahiro Matsuno; Shinji Kitajima; Yasunori Iwata; Norihiko Sakai; Kiyotaka Nagahama; Yo Niida; Takao Saito; Hitoshi Yokoyama; Takashi Wada
Journal:  Case Rep Nephrol Dial       Date:  2022-06-10

4.  Focal segmental glomerulosclerosis with heterozygous apolipoprotein E5 (Glu3Lys).

Authors:  Masaru Sasaki; Tetsuhiko Yasuno; Kenji Ito; Akira Matsunaga; Satoshi Hisano; Yasuhiro Abe; Katsuhisa Miyake; Kosuke Masutani; Hitoshi Nakashima; Takao Saito
Journal:  CEN Case Rep       Date:  2018-05-08

Review 5.  Metabolism, energetics, and lipid biology in the podocyte - cellular cholesterol-mediated glomerular injury.

Authors:  Sandra Merscher; Christopher E Pedigo; Armando J Mendez
Journal:  Front Endocrinol (Lausanne)       Date:  2014-10-14       Impact factor: 5.555

Review 6.  Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor.

Authors:  Virginia J Savin; Mukut Sharma; Jianping Zhou; David Genochi; Ram Sharma; Tarak Srivastava; Amna Ilahe; Pooja Budhiraja; Aditi Gupta; Ellen T McCarthy
Journal:  Biomed Res Int       Date:  2017-08-10       Impact factor: 3.411

Review 7.  Urinary Protein and Peptide Markers in Chronic Kidney Disease.

Authors:  Natalia Chebotareva; Anatoliy Vinogradov; Valerie McDonnell; Natalia V Zakharova; Maria I Indeykina; Sergey Moiseev; Evgeny N Nikolaev; Alexey S Kononikhin
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

8.  Association of APOE polymorphism with chronic kidney disease in a nationally representative sample: a Third National Health and Nutrition Examination Survey (NHANES III) Genetic Study.

Authors:  Audrey Y Chu; Rulan S Parekh; Brad C Astor; Josef Coresh; Yvette Berthier-Schaad; Michael W Smith; Alan R Shuldiner; Wen Hong L Kao
Journal:  BMC Med Genet       Date:  2009-10-23       Impact factor: 2.103

Review 9.  Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  Virginia J Savin; Ellen T McCarthy; Mukut Sharma
Journal:  Kidney Res Clin Pract       Date:  2012-10-16

Review 10.  High-Density Lipoproteins and the Kidney.

Authors:  Arianna Strazzella; Alice Ossoli; Laura Calabresi
Journal:  Cells       Date:  2021-03-31       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.